TAK (Takeda Pharmaceutical Co) Intangible Assets: $57,710 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TAK Takeda Pharmaceutical Co Ltd TAK
77 GF Score
Price $17.39
GF Value $14.09
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Intangible Assets?

Takeda Pharmaceutical Co TAK -0.11% 77 Intangible Assets is $57,710 Mil as of Jun. 2026. GuruFocus rates TAK with a GF Score™ of 77/100 and a GF Value™ of $14.09 (Modestly Overvalued). The stock has 10 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Takeda Pharmaceutical Co's intangible assets for the quarter that ended in Jun. 2026 was $57,710 Mil.


Takeda Pharmaceutical Co  (NYSE:TAK) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Takeda Pharmaceutical Co Intangible Assets Related Terms


Takeda Pharmaceutical Co Intangible Assets Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Intangible Assets Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69,374.89 67,784.59 64,643.18 60,084.09 58,156.04

Takeda Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60,341.93 59,047.42 59,448.39 58,156.04 57,710.13
TAK
77GF Score
Takeda Pharmaceutical Co Ltd TAK
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of $57,710 Mil mean?
Takeda Pharmaceutical Co (TAK) has a Intangible Assets of $57,710 Mil as of Jun. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Intangible Assets too high?
Takeda Pharmaceutical Co's current Intangible Assets is $57,710 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Intangible Assets compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Intangible Assets of $57,710 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Drug Manufacturers company?
A good Intangible Assets depends on the Drug Manufacturers industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Intangible Assets is $57,710 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TAK) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.09, compared to a current price of $17.39 — trading 23.4% above its estimated fair value. The current Intangible Assets is $57,710 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TAK), the current Intangible Assets is $57,710 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TAK) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of $17.39 is trading 23.4% above its estimated GF Value™ of $14.09. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TAK:

  • Intangible Assets: $57,710 Mil
  • GF Value™: $14.09 vs. price of $17.39 (23.4% above fair value)
  • GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the TAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
77GF Score

Get the complete analysis for TAK

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.39
Price
$14.09
GF Value